S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
Log in
NASDAQ:ORTX

Orchard Therapeutics Competitors

$6.86
-0.50 (-6.79 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.72
Now: $6.86
$7.49
50-Day Range
$5.62
MA: $7.06
$9.08
52-Week Range
$3.76
Now: $6.86
$12.38
Volume856,099 shs
Average Volume2.95 million shs
Market Capitalization$667.23 million
P/E RatioN/A
Dividend YieldN/A
Beta1.31

Competitors

Orchard Therapeutics (NASDAQ:ORTX) Vs. SRNE, ALVR, KYMR, BCRX, BLUE, and VCEL

Should you be buying ORTX stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Orchard Therapeutics, including Sorrento Therapeutics (SRNE), AlloVir (ALVR), Kymera Therapeutics (KYMR), BioCryst Pharmaceuticals (BCRX), bluebird bio (BLUE), and Vericel (VCEL).

Sorrento Therapeutics (NASDAQ:SRNE) and Orchard Therapeutics (NASDAQ:ORTX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Sorrento Therapeutics and Orchard Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sorrento Therapeutics00403.00
Orchard Therapeutics00403.00

Sorrento Therapeutics currently has a consensus price target of $28.75, suggesting a potential upside of 226.33%. Orchard Therapeutics has a consensus price target of $14.75, suggesting a potential upside of 115.01%. Given Sorrento Therapeutics' higher probable upside, equities analysts clearly believe Sorrento Therapeutics is more favorable than Orchard Therapeutics.

Profitability

This table compares Sorrento Therapeutics and Orchard Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sorrento Therapeutics-698.01%-314.06%-43.60%
Orchard TherapeuticsN/A-65.65%-47.92%

Institutional and Insider Ownership

27.4% of Sorrento Therapeutics shares are held by institutional investors. Comparatively, 66.6% of Orchard Therapeutics shares are held by institutional investors. 3.4% of Sorrento Therapeutics shares are held by company insiders. Comparatively, 4.2% of Orchard Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Sorrento Therapeutics and Orchard Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sorrento Therapeutics$31.43 million78.73$-292,070,000.00($2.12)-4.16
Orchard Therapeutics$2.51 million265.83$-163,420,000.00($1.75)-3.92

Orchard Therapeutics has lower revenue, but higher earnings than Sorrento Therapeutics. Sorrento Therapeutics is trading at a lower price-to-earnings ratio than Orchard Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Sorrento Therapeutics has a beta of 2.7, suggesting that its stock price is 170% more volatile than the S&P 500. Comparatively, Orchard Therapeutics has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500.

Summary

Orchard Therapeutics beats Sorrento Therapeutics on 8 of the 12 factors compared between the two stocks.

AlloVir (NASDAQ:ALVR) and Orchard Therapeutics (NASDAQ:ORTX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for AlloVir and Orchard Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AlloVir00403.00
Orchard Therapeutics00403.00

AlloVir currently has a consensus price target of $48.75, suggesting a potential upside of 41.18%. Orchard Therapeutics has a consensus price target of $14.75, suggesting a potential upside of 115.01%. Given Orchard Therapeutics' higher probable upside, analysts clearly believe Orchard Therapeutics is more favorable than AlloVir.

Profitability

This table compares AlloVir and Orchard Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AlloVirN/AN/AN/A
Orchard TherapeuticsN/A-65.65%-47.92%

Institutional and Insider Ownership

32.1% of AlloVir shares are held by institutional investors. Comparatively, 66.6% of Orchard Therapeutics shares are held by institutional investors. 1.0% of AlloVir shares are held by company insiders. Comparatively, 4.2% of Orchard Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares AlloVir and Orchard Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AlloVirN/AN/AN/AN/AN/A
Orchard Therapeutics$2.51 million265.83$-163,420,000.00($1.75)-3.92

AlloVir has higher earnings, but lower revenue than Orchard Therapeutics.

Summary

Orchard Therapeutics beats AlloVir on 4 of the 6 factors compared between the two stocks.

Kymera Therapeutics (NASDAQ:KYMR) and Orchard Therapeutics (NASDAQ:ORTX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Kymera Therapeutics and Orchard Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kymera Therapeutics02402.67
Orchard Therapeutics00403.00

Kymera Therapeutics currently has a consensus price target of $50.3333, suggesting a potential upside of 9.75%. Orchard Therapeutics has a consensus price target of $14.75, suggesting a potential upside of 115.01%. Given Orchard Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Orchard Therapeutics is more favorable than Kymera Therapeutics.

Profitability

This table compares Kymera Therapeutics and Orchard Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kymera TherapeuticsN/AN/AN/A
Orchard TherapeuticsN/A-65.65%-47.92%

Institutional and Insider Ownership

37.8% of Kymera Therapeutics shares are held by institutional investors. Comparatively, 66.6% of Orchard Therapeutics shares are held by institutional investors. 4.2% of Orchard Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Kymera Therapeutics and Orchard Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kymera TherapeuticsN/AN/AN/AN/AN/A
Orchard Therapeutics$2.51 million265.83$-163,420,000.00($1.75)-3.92

Kymera Therapeutics has higher earnings, but lower revenue than Orchard Therapeutics.

Summary

Orchard Therapeutics beats Kymera Therapeutics on 5 of the 7 factors compared between the two stocks.

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Orchard Therapeutics (NASDAQ:ORTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for BioCryst Pharmaceuticals and Orchard Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioCryst Pharmaceuticals03802.73
Orchard Therapeutics00403.00

BioCryst Pharmaceuticals currently has a consensus price target of $11.3750, suggesting a potential upside of 4.17%. Orchard Therapeutics has a consensus price target of $14.75, suggesting a potential upside of 115.01%. Given Orchard Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Orchard Therapeutics is more favorable than BioCryst Pharmaceuticals.

Profitability

This table compares BioCryst Pharmaceuticals and Orchard Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioCryst Pharmaceuticals-233.45%-328.70%-71.11%
Orchard TherapeuticsN/A-65.65%-47.92%

Institutional and Insider Ownership

72.0% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 66.6% of Orchard Therapeutics shares are held by institutional investors. 4.3% of BioCryst Pharmaceuticals shares are held by company insiders. Comparatively, 4.2% of Orchard Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares BioCryst Pharmaceuticals and Orchard Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioCryst Pharmaceuticals$48.83 million39.70$-108,900,000.00($0.94)-11.62
Orchard Therapeutics$2.51 million265.83$-163,420,000.00($1.75)-3.92

BioCryst Pharmaceuticals has higher revenue and earnings than Orchard Therapeutics. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Orchard Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

BioCryst Pharmaceuticals has a beta of 3.03, suggesting that its stock price is 203% more volatile than the S&P 500. Comparatively, Orchard Therapeutics has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500.

bluebird bio (NASDAQ:BLUE) and Orchard Therapeutics (NASDAQ:ORTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for bluebird bio and Orchard Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
bluebird bio013402.24
Orchard Therapeutics00403.00

bluebird bio currently has a consensus price target of $68.4667, suggesting a potential upside of 145.05%. Orchard Therapeutics has a consensus price target of $14.75, suggesting a potential upside of 115.01%. Given bluebird bio's higher probable upside, equities analysts clearly believe bluebird bio is more favorable than Orchard Therapeutics.

Profitability

This table compares bluebird bio and Orchard Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
bluebird bio-256.84%-45.78%-35.14%
Orchard TherapeuticsN/A-65.65%-47.92%

Institutional and Insider Ownership

94.3% of bluebird bio shares are held by institutional investors. Comparatively, 66.6% of Orchard Therapeutics shares are held by institutional investors. 3.6% of bluebird bio shares are held by company insiders. Comparatively, 4.2% of Orchard Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares bluebird bio and Orchard Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
bluebird bio$44.67 million42.00$-789,610,000.00($14.31)-1.95
Orchard Therapeutics$2.51 million265.83$-163,420,000.00($1.75)-3.92

Orchard Therapeutics has lower revenue, but higher earnings than bluebird bio. Orchard Therapeutics is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

bluebird bio has a beta of 1.89, suggesting that its stock price is 89% more volatile than the S&P 500. Comparatively, Orchard Therapeutics has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500.

Summary

bluebird bio beats Orchard Therapeutics on 7 of the 13 factors compared between the two stocks.

Vericel (NASDAQ:VCEL) and Orchard Therapeutics (NASDAQ:ORTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings and price targets for Vericel and Orchard Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vericel02602.75
Orchard Therapeutics00403.00

Vericel currently has a consensus price target of $49.00, suggesting a potential upside of 21.26%. Orchard Therapeutics has a consensus price target of $14.75, suggesting a potential upside of 115.01%. Given Orchard Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Orchard Therapeutics is more favorable than Vericel.

Profitability

This table compares Vericel and Orchard Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vericel0.12%0.13%0.10%
Orchard TherapeuticsN/A-65.65%-47.92%

Institutional & Insider Ownership

93.1% of Vericel shares are held by institutional investors. Comparatively, 66.6% of Orchard Therapeutics shares are held by institutional investors. 4.3% of Vericel shares are held by company insiders. Comparatively, 4.2% of Orchard Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Vericel and Orchard Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vericel$117.85 million15.76$-9,660,000.00$0.18224.50
Orchard Therapeutics$2.51 million265.83$-163,420,000.00($1.75)-3.92

Vericel has higher revenue and earnings than Orchard Therapeutics. Orchard Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Vericel has a beta of 3.11, suggesting that its share price is 211% more volatile than the S&P 500. Comparatively, Orchard Therapeutics has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500.

Summary

Vericel beats Orchard Therapeutics on 10 of the 14 factors compared between the two stocks.


Orchard Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$8.81-3.0%$2.47 billion$31.43 million-6.03Gap Up
AlloVir logo
ALVR
AlloVir
1.4$34.53-7.5%$2.25 billionN/A0.00Insider Selling
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
0.8$45.86-1.9%$2.04 billionN/A0.00
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.1$10.92-8.7%$1.94 billion$48.83 million-14.37
bluebird bio logo
BLUE
bluebird bio
1.8$27.94-5.0%$1.88 billion$44.67 million-2.54Analyst Report
Vericel logo
VCEL
Vericel
1.5$40.41-4.2%$1.86 billion$117.85 million-4,041,000.00Analyst Report
Analyst Revision
Scholar Rock logo
SRRK
Scholar Rock
1.3$50.60-1.7%$1.70 billion$20.49 million-21.00Upcoming Earnings
News Coverage
Gap Up
Ocugen logo
OCGN
Ocugen
1.1$8.97-16.6%$1.69 billionN/A-6.06Analyst Report
Unusual Options Activity
Gap Up
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.1$39.07-2.5%$1.68 billionN/A0.00
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.23-0.3%$1.61 billion$102.43 million-18.72Analyst Downgrade
Analyst Revision
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$71.65-16.2%$1.59 billionN/A-48.41Earnings Announcement
Analyst Upgrade
Analyst Revision
Translate Bio logo
TBIO
Translate Bio
1.4$21.29-0.8%$1.58 billion$7.80 million-19.90Upcoming Earnings
Analyst Revision
News Coverage
Replimune Group logo
REPL
Replimune Group
1.5$32.30-1.3%$1.50 billionN/A-18.25News Coverage
REGENXBIO logo
RGNX
REGENXBIO
1.8$39.21-2.4%$1.47 billion$35.23 million-15.81Earnings Announcement
Analyst Downgrade
Analyst Revision
FMTX
Forma Therapeutics
1.8$33.42-8.4%$1.38 billion$100.56 million0.00Decrease in Short Interest
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.6$15.89-0.4%$1.33 billionN/A-3.44Earnings Announcement
Analyst Upgrade
Analyst Revision
Alector logo
ALEC
Alector
1.3$16.25-1.0%$1.29 billion$21.22 million-7.29Analyst Upgrade
Immunovant logo
IMVT
Immunovant
1.8$13.08-7.0%$1.28 billionN/A-10.14Increase in Short Interest
PCVX
Vaxcyte
1.8$23.62-9.4%$1.20 billionN/A0.00Insider Selling
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$15.25-1.2%$1.11 billion$356.07 million7.47Analyst Report
Mesoblast logo
MESO
Mesoblast
1.4$9.18-0.3%$1.08 billion$32.16 million-10.43Earnings Announcement
Analyst Upgrade
Analyst Revision
Cortexyme logo
CRTX
Cortexyme
1.3$36.37-3.2%$1.07 billionN/A-15.15Earnings Announcement
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$10.96-3.1%$1.07 billion$250,000.00-8.63Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Inhibrx logo
INBX
Inhibrx
1.7$26.56-9.9%$1.00 billionN/A0.00
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$19.25-1.6%$903.15 million$69.89 million-4.59
Passage Bio logo
PASG
Passage Bio
1.9$19.43-2.7%$892.17 millionN/A0.00Earnings Announcement
Analyst Upgrade
News Coverage
Gap Down
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$23.40-7.7%$883.61 millionN/A0.00Earnings Announcement
Analyst Report
News Coverage
Gap Down
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$23.73-8.0%$857.03 millionN/A-3.92News Coverage
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.7$10.40-10.4%$844.29 millionN/A-4.86
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.54-12.1%$821.06 millionN/A0.00
Cellectis logo
CLLS
Cellectis
1.2$19.31-4.3%$820.41 million$22.99 million-10.27
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.5$24.06-6.9%$804.13 millionN/A-9.94
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.29-4.7%$783.28 million$42.74 million-225.44
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.6$5.01-4.8%$775.44 million$1.12 million-5.06Analyst Upgrade
Vaxart logo
VXRT
Vaxart
1.3$5.92-7.4%$697.18 million$9.86 million-10.03Analyst Report
Gap Up
Athira Pharma logo
ATHA
Athira Pharma
2.2$19.29-6.8%$626.64 millionN/A0.00Decrease in Short Interest
News Coverage
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.4$30.61-8.2%$622.00 millionN/A0.00Increase in Short Interest
Gap Down
Agenus logo
AGEN
Agenus
1.6$3.16-7.3%$600.87 million$150.05 million-2.90
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$11.02-3.1%$578.33 million$22.24 million-5.48Upcoming Earnings
Analyst Report
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.9$9.28-17.0%$573.69 millionN/A-1.35
Compugen logo
CGEN
Compugen
1.4$8.16-9.2%$558.31 million$17.80 million-22.05Analyst Downgrade
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.02-7.6%$551.49 million$14.75 million-2.15Gap Up
Curis logo
CRIS
Curis
1.3$9.13-6.4%$537.00 million$10 million-11.13Increase in Short Interest
MeiraGTx logo
MGTX
MeiraGTx
1.4$13.90-2.5%$533.93 million$13.29 million-9.86Upcoming Earnings
News Coverage
Solid Biosciences logo
SLDB
Solid Biosciences
1.1$8.83-12.0%$533.77 millionN/A-4.29Upcoming Earnings
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.7$20.44-2.7%$529.60 millionN/A-5.89
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.4$11.45-6.7%$519.76 million$147.87 million-3.80Analyst Upgrade
Gap Up
Gritstone Oncology logo
GRTS
Gritstone Oncology
1.6$13.59-1.8%$513.21 million$4.36 million-4.75Upcoming Earnings
Increase in Short Interest
HARP
Harpoon Therapeutics
1.5$19.14-4.3%$485.77 million$5.78 million-8.99Upcoming Earnings
News Coverage
Gap Up
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.5$11.43-2.8%$476.93 millionN/A0.00Upcoming Earnings
This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.